TEL AVIV, Israel, March 8, 2017 -- Definitive agreement grants KuhnilPharmaceutical Co. Ltd.an exclusive license tomanufactureand marketKIT-302 in South Korea 

 

TransactionisKitov's FirstLicenseAgreement for KIT-302 

Celecoxibis the leadingNSAIDproduct in South Koreawithreportedsales of over $55 Million in 2015 

 

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced today that the Company has signed a definitive License Agreement for its lead product candidate, KIT-302, which was developed to simultaneously treat pain caused by osteoarthritis and to treat hypertension, for the territory of South Korea with Kuhnil Pharmaceutical Co. Ltd., a leading South Korea-based pharmaceutical company.  Upon receipt of marketing authorization in South Korea, Kuhnil will have the exclusive right and license to manufacture, distribute and sell KIT-302 in South Korea.  Kuhnil will be responsible for seeking regulatory approval for KIT-302 in South Korea.

MADISON, Wis., March 08, 2017 -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces it has entered into a licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property rights covering the method of use (MOU) for the company’s lead PDC compound, CLR 131, in multiple myeloma.  

 

“We are extremely pleased to further strengthen our relationship with Cellectar,” said Carrie Thome, WARF director of investments.  “WARF’s ability to use the many assets that exist in our portfolio to help advance an important new technology towards ultimate commercialization is a wonderful example of the power of the unique WARF model that combines world class technology transfer and investment management capabilities.”

IV OCR-002 statistically significantly normalized ammonia faster than standard of care

Ammonia reduction statistically significantly correlated with clinical improvement in HE symptoms

Ocera plans to meet with FDA in Q3 2017 to inform development paths forward for IV OCR-002

Company presentation scheduled for today, March 8, 2017 at 11:20 AM ET

 

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 08, 2017 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced it will report additional encouraging results from its Phase 2b STOP-HE study of intravenous (IV) OCR-002 in hospitalized patients with Hepatic Encephalopathy (HE) at the Cowen and Company 37th Annual Healthcare Conference at 11:20 AM Eastern Time today.

- ICT-107 Protocol Amendment Being Implemented in US Clinical Sites; Amended Protocol Submissions Underway in Europe and Canada.

- Successful Sequencing of Target T Cell Receptor Gene is Key Step in Advancing toward Identification of Potential Clinical Candidate in Stem-to-T-Cell Program.

 

LOS ANGELES, March 6, 2017  -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) today provided an update on the Company's ICT-107 phase 3 registration trial in newly diagnosed glioblastoma, and announced advances in its Stem-to-T-cell Research program.